Long-Term Debt - Novartis Note - Additional Information (Details) - USD ($) |
1 Months Ended | 6 Months Ended | |
|---|---|---|---|
May 31, 2005 |
Jun. 30, 2017 |
Dec. 31, 2016 |
|
| Novartis Note [Member] | |||
| Debt Instrument [Line Items] | |||
| Maturity date | Jun. 30, 2015 | ||
| Research and development expenses funded through loan facility, maximum | 75.00% | ||
| Maximum borrowing capacity under loan agreement | $ 50,000,000 | ||
| Interest rate at period end | 3.44% | ||
| Outstanding principal balance | $ 14,300,000 | $ 14,100,000 | |
| Novartis Note [Member] | Six-month LIBOR [Member] | |||
| Debt Instrument [Line Items] | |||
| Basis spread on variable rate | 2.00% | ||
| Secured Note Amendment [Member] | |||
| Debt Instrument [Line Items] | |||
| Maturity date | Sep. 30, 2020 | ||
| Reduction in outstanding principal amount | $ 7,300,000 |
| X | ||||||||||
- Definition Percentage points added to the reference rate to compute the variable rate on the debt instrument. No definition available.
|
| X | ||||||||||
- Definition Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Decrease for amounts of indebtedness forgiven by the holder of the debt instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company. No definition available.
|
| X | ||||||||||
- Definition The maximum borrowing capacity for a debt instrument under the loan agreement. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|